This segment focuses on the research, development, and clinical evaluation of novel therapies for various cancers. Syros utilizes its expertise in gene control to develop targeted treatments. Key activities include identifying and validating therapeutic targets, conducting preclinical studies, and managing clinical trials. The company's lead product candidates, such as SY-1425 (a selective retinoic acid receptor alpha agonist) and SY-5609 (a cyclin-dependent kinase 7 inhibitor), are being evaluated in clinical trials for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and select advanced solid tumors. The goal is to improve patient outcomes by providing more effective and less toxic cancer treatments. Syros is positioned to address unmet needs in cancer treatment through its innovative approach to gene regulation. Future opportunities include expanding the clinical development of existing candidates and exploring new targets. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to clinical trial protocols. Partnerships and collaborations are essential for advancing research and development efforts.

This segment concentrates on developing treatments for hematological malignancies and rare genetic diseases. Syros is leveraging its gene control platform to address conditions with significant unmet medical needs. Research and development efforts include identifying and validating targets in blood cancers and rare genetic disorders, conducting preclinical studies, and managing clinical trials. The company's pipeline includes SY-2101, a novel oral form of arsenic trioxide for treating acute promyelocytic leukemia (APL). The focus is on improving patient outcomes by providing targeted therapies. Syros aims to establish itself as a leader in treating hematological disorders and rare diseases through its innovative approach. Future opportunities include expanding the clinical development of existing candidates and exploring new targets. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to clinical trial protocols. Partnerships and collaborations are essential for advancing research and development efforts.